Understanding Urinary Tract Infections (UTIs) through Ayurveda: A Study on Mutrakrichra and the Role of Gorakshaganja (Aerva lanata) Kwath in Its Management

A Conceptual and Clinical Study on Mutrakrichra (Dysuria) with Special Reference to Urinary Tract Infection (UTI) and Its Management Using Gorakshaganja (Aerva lanata Juss.) Decoction - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/086746

Enrollment

Registered

2025-05-13

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N390- Urinary tract infection, site notspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients who present with sign and symptoms of Mutrakrichra w.s.r.to U.T.I. 2.Patients of either sex in the age group of 18-70yrs. 3.Patientswillingfortrialandthepatientswhohavenoseriousorganicormetabolicailmentsrequiringimmediate medical/surgical intervention. 4.Pregnancy

Exclusion criteria

Exclusion criteria: 1.Patients not willing for trial. 2.Patients below the age of 18 yrs and above the age of 70yrs. 3.Patient having other organic diseases with Urinary tract infection. 4.Case of associated obstructed uropathy and suffering from chronic illness requiring immediate hospitalization.

Design outcomes

Primary

Measure	Time frame
Effectiveness of Norfloxacin and Gorakshaganja in Treating Urinary Tract Infections (UTIs), based on: Relief from Symptoms: Improvement in common UTI complaints such as burning while urinating, frequent urination, urgent need to urinate, and lower abdominal pain. Clearing the Infection: A urine test showing no growth of infection-causing bacteria (negative urine culture), indicating the infection has been cured. Timepoint: Day 0 (Before Starting Treatment): Patient s symptoms are recorded. Urine tests (routine and culture) are done to confirm UTI. Day 7 (One Week After Starting Treatment): Symptoms are checked again to see improvement. Helps assess early effect of the medicine. Day 14 (End of Treatment): Final check-up is done. Symptoms are reviewed and urine tests are repeated to see if the infection is cured.	—

Measure

Time frame

Effectiveness of Norfloxacin and Gorakshaganja in Treating Urinary Tract Infections (UTIs), based on: Relief from Symptoms: Improvement in common UTI complaints such as burning while urinating, frequent urination, urgent need to urinate, and lower abdominal pain. Clearing the Infection: A urine test showing no growth of infection-causing bacteria (negative urine culture), indicating the infection has been cured. Timepoint: Day 0 (Before Starting Treatment): Patient s symptoms are recorded. Urine tests (routine and culture) are done to confirm UTI. Day 7 (One Week After Starting Treatment): Symptoms are checked again to see improvement. Helps assess early effect of the medicine. Day 14 (End of Treatment): Final check-up is done. Symptoms are reviewed and urine tests are repeated to see if the infection is cured.

—

Secondary

Measure	Time frame
1. Safety: Incidence and severity of adverse effects. 2. Recurrence Rate: UTI recurrence within 14-28 days. 3. Quality of Life (QoL): Improvement in patient-reported outcomes. 4. Time to Symptom Resolution: Duration for complete symptom relief. 5. Cost-effectiveness: Economic comparison of treatmentsTimepoint: 1. Baseline (Day 0): Initial assessment (symptoms, QoL, clinical parameters). 2. Mid-treatment (Day 3-5): Monitor symptom improvement and adverse effects. 3. End of Treatment (Day 7-10): Evaluate symptom resolution, safety, and QoL. 4. Follow-up (Day 14): Assess recurrence and residual effects. 5. Optional Follow-up (Day 28): Late recurrence and adverse effects.	—

Measure

Time frame

1. Safety: Incidence and severity of adverse effects. 2. Recurrence Rate: UTI recurrence within 14-28 days. 3. Quality of Life (QoL): Improvement in patient-reported outcomes. 4. Time to Symptom Resolution: Duration for complete symptom relief. 5. Cost-effectiveness: Economic comparison of treatmentsTimepoint: 1. Baseline (Day 0): Initial assessment (symptoms, QoL, clinical parameters). 2. Mid-treatment (Day 3-5): Monitor symptom improvement and adverse effects. 3. End of Treatment (Day 7-10): Evaluate symptom resolution, safety, and QoL. 4. Follow-up (Day 14): Assess recurrence and residual effects. 5. Optional Follow-up (Day 28): Late recurrence and adverse effects.

—

Countries

India

Contacts

Public ContactDr Akhilesh Kumar Srivastava

Rajiv Gandhi Government Post Graduate Ayurvedic College and Hospital

drakhilesh.srivastava@yahoo.com6230118318

Outcome results